Minji Lee
Minji Lee has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Hyun-Ja Ko
Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea
2 shared publications - Kwang Soon Kim
Department of Life Sciences, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea
2 shared publications Mankyu Ji
Research Institute of NeoImmuneTech, Co., Ltd, Pohang, Korea (the Republic of)
2 shared publicationsSeungtae Baek
Research Institute of NeoImmuneTech, Co., Ltd, Pohang, Korea (the Republic of)
2 shared publications- Sung-Wook Hong
Department of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology (POSTECH), Pohang, Republic of Korea.
2 shared publications - You Jeong Lee
Research Institute of Pharmaceutical Sciences, Seoul National University, College of Pharmacy, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 12 March 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (3) , e008001
rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors
Background: Recombinant human interleukin (rhIL)-7-hyFc (efineptakin alfa; NT-I7) is a potent T-cell amplifier, with two IL-7 molecules fused to IgD/IgG4 elements. rhIL-7-hyFc promotes extensive infiltration of CD8 + T cells into the tumor, concurrently increasing the numbers of intratumoral PD-1 + CD8 + T cells. The hIL-2/TCB2 complex (SLC-3010) inhibits tumor growth by preferential activation of CD122 (IL-2Rβ) high CD8 + T cells and natural killer cells, over regulatory T cells (Tregs). We investigated the underlying mechanisms of rhIL-7-hyFc and hIL-2/TCB2c antitumor activity and the potential synergistic efficacy, specifically focusing on tumor-specific CD8 + cells within the tumor and the tumor-draining lymph nodes (tdLN). Methods: MC38 and CT26 tumor-bearing mice were administered with 10 mg/kg rhIL-7-hyFc intramuscularly and 0.9 mg/kg hIL-2/TCB2c intravenously. Anti-PD-1 monoclonal antibody was administered intraperitoneally three times at 3-day intervals at a dose of 5 mg/kg. Tumor volume was measured to assess efficacy. To compare the composition of immune cells between each monotherapy and the combination therapy, we analyzed tumors and tdLNs by flow cytometry. Results: Our data demonstrate that the combination of rhIL-7-hyFc and hIL-2/TCB2c increases efficacy and generates an immune-stimulatory tumor microenvironment (TME). The TME is characterized by an increased infiltration of tumor-specific CD8 + T cells, and a decreased frequency of CD39 high TIM-3 + Treg cells. Most importantly, rhIL-7-hyFc increases infiltration of a CD62L + Ly108 + early progenitor population of exhausted CD8 + T cells (T PEX ), which may retain long-term proliferation capacity and replenish functional effector CD8 + T cells. hIL-2/TCB2c induces differentiation of CD62L + Ly108 + T PEX rapidly into CD101 + terminally differentiated subsets (terminally exhausted T cell (T EX term )). Our study also demonstrates that rhIL-7-hyFc significantly enhances the proliferation rate of T PEX in the tdLNs, positively correlating with their abundance within the tumor. Moreover, rhIL-7-hyFc and hIL-2/TCB2c can overcome the limited therapeutic effectiveness of PD-1 blockade, culminating in the complete regression of tumors. Conclusions: rhIL-7-hyFc can expand and maintain the progenitor pool of exhausted CD8 + T cells, whereas hIL-2/TCB2c promotes their differentiation into T EX term . Together, this induces an immune-stimulatory TME that improves the efficacy of checkpoint blockade.
- 12 March 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (3) , e008001
Open AccessrhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors
Background: Recombinant human interleukin (rhIL)-7-hyFc (efineptakin alfa; NT-I7) is a potent T-cell amplifier, with two IL-7 molecules fused to IgD/IgG4 elements. rhIL-7-hyFc promotes extensive infiltration of CD8 + T cells into the tumor, concurrently increasing the numbers of intratumoral PD-1 + CD8 + T cells. The hIL-2/TCB2 complex (SLC-3010) inhibits tumor growth by preferential activation of CD122 (IL-2Rβ) high CD8 + T cells and natural killer cells, over regulatory T cells (Tregs). We investigated the underlying mechanisms of rhIL-7-hyFc and hIL-2/TCB2c antitumor activity and the potential synergistic efficacy, specifically focusing on tumor-specific CD8 + cells within the tumor and the tumor-draining lymph nodes (tdLN). Methods: MC38 and CT26 tumor-bearing mice were administered with 10 mg/kg rhIL-7-hyFc intramuscularly and 0.9 mg/kg hIL-2/TCB2c intravenously. Anti-PD-1 monoclonal antibody was administered intraperitoneally three times at 3-day intervals at a dose of 5 mg/kg. Tumor volume was measured to assess efficacy. To compare the composition of immune cells between each monotherapy and the combination therapy, we analyzed tumors and tdLNs by flow cytometry. Results: Our data demonstrate that the combination of rhIL-7-hyFc and hIL-2/TCB2c increases efficacy and generates an immune-stimulatory tumor microenvironment (TME). The TME is characterized by an increased infiltration of tumor-specific CD8 + T cells, and a decreased frequency of CD39 high TIM-3 + Treg cells. Most importantly, rhIL-7-hyFc increases infiltration of a CD62L + Ly108 + early progenitor population of exhausted CD8 + T cells (T PEX ), which may retain long-term proliferation capacity and replenish functional effector CD8 + T cells. hIL-2/TCB2c induces differentiation of CD62L + Ly108 + T PEX rapidly into CD101 + terminally differentiated subsets (terminally exhausted T cell (T EX term )). Our study also demonstrates that rhIL-7-hyFc significantly enhances the proliferation rate of T PEX in the tdLNs, positively correlating with their abundance within the tumor. Moreover, rhIL-7-hyFc and hIL-2/TCB2c can overcome the limited therapeutic effectiveness of PD-1 blockade, culminating in the complete regression of tumors. Conclusions: rhIL-7-hyFc can expand and maintain the progenitor pool of exhausted CD8 + T cells, whereas hIL-2/TCB2c promotes their differentiation into T EX term . Together, this induces an immune-stimulatory TME that improves the efficacy of checkpoint blockade.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 4199
Abstract 4199: rhIL-7-hyFc (efineptakinalpha; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex
RhIL-7-hyFc (efineptakin-alfa; NT-I7) is a potent T cell amplifier, with a homodimeric interleukin-7 (IL-7) fused to the hybridizing IgD/IgG4 immunoglobulin domain. Previous work has shown that in mice, NT-I7 dramatically increases tumor-infiltrating CD8+ T cells while reducing the frequency of PD-1+ CD8+ T cells in the tumor. There is also significant expansion of Central Memory (CM)-phenotype CD8+ T cells (CD62L+CD44+) in the tumor and tumor draining lymph node. Here, we investigated the anti-tumor effect of NT-I7 in combination with a T cell activator, SLC-3010 (hIL-2/TCB2c complex), in MC38 tumor-bearing mice. Because TCB2 is an antibody specific for IL-2 that blocks interaction of IL-2 and IL-2Rα (CD25), SLC-3010 can selectively activate T cells while disfavoring Treg activation. Mice were administered a single dose of NT-I7 or SLC-3010 via intramuscular or intravenous injection, respectively. The combination of NT-I7 with SLC-3010 enhanced the anti-tumor response with increased number and frequency of CD8+ T cells as well as granzyme B expression in the tumor. The number of CD8+ T cells peaked at day 4 and day 7 by SLC-3010 and NT-I7, respectively. The number of Tregs in the tumor was slightly increased by NT-I7 and SLC-3010, but it was not statistically significant. Interestingly, NT-I7, but not SLC-3010, increased the frequency of PD-1+TCF-1+TOX- stem-like CD8+ T cells in the draining lymph node. Meanwhile, SLC-3010 significantly increased the number of PD-1+ CD8+ T cells in the tumor. Our data suggests that NT-I7 can be applied in combination with other immunotherapies such as IL-2 to enhance the anti-tumor response. Citation Format: Seungtae Baek, Sun-Kyoung Im, Minji Lee, Mankyu Ji, Miyoung Kim, Daeun Kim, Jun Young Lee, Donghoon Choi. rhIL-7-hyFc (efineptakinalpha; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4199.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 4199
Open AccessAbstract 4199: rhIL-7-hyFc (efineptakinalpha; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex
RhIL-7-hyFc (efineptakin-alfa; NT-I7) is a potent T cell amplifier, with a homodimeric interleukin-7 (IL-7) fused to the hybridizing IgD/IgG4 immunoglobulin domain. Previous work has shown that in mice, NT-I7 dramatically increases tumor-infiltrating CD8+ T cells while reducing the frequency of PD-1+ CD8+ T cells in the tumor. There is also significant expansion of Central Memory (CM)-phenotype CD8+ T cells (CD62L+CD44+) in the tumor and tumor draining lymph node. Here, we investigated the anti-tumor effect of NT-I7 in combination with a T cell activator, SLC-3010 (hIL-2/TCB2c complex), in MC38 tumor-bearing mice. Because TCB2 is an antibody specific for IL-2 that blocks interaction of IL-2 and IL-2Rα (CD25), SLC-3010 can selectively activate T cells while disfavoring Treg activation. Mice were administered a single dose of NT-I7 or SLC-3010 via intramuscular or intravenous injection, respectively. The combination of NT-I7 with SLC-3010 enhanced the anti-tumor response with increased number and frequency of CD8+ T cells as well as granzyme B expression in the tumor. The number of CD8+ T cells peaked at day 4 and day 7 by SLC-3010 and NT-I7, respectively. The number of Tregs in the tumor was slightly increased by NT-I7 and SLC-3010, but it was not statistically significant. Interestingly, NT-I7, but not SLC-3010, increased the frequency of PD-1+TCF-1+TOX- stem-like CD8+ T cells in the draining lymph node. Meanwhile, SLC-3010 significantly increased the number of PD-1+ CD8+ T cells in the tumor. Our data suggests that NT-I7 can be applied in combination with other immunotherapies such as IL-2 to enhance the anti-tumor response. Citation Format: Seungtae Baek, Sun-Kyoung Im, Minji Lee, Mankyu Ji, Miyoung Kim, Daeun Kim, Jun Young Lee, Donghoon Choi. rhIL-7-hyFc (efineptakinalpha; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4199.
- 15 May 2022
- Published by Korean Association For Learner-Centered Curriculum And Instruction in Korean Association For Learner-Centered Curriculum And Instruction
- Vol. 22 (9) , 59-78
The Perception and Practice of Early Childhood Teacher’s Decision-Making Involvement
???? ?? ?????? ?????Ʊ?????? ?ǻ???? ?????? ???? ?νİ? ?????? ????? ?˾ƺ??? ?? ?????? ?ξ???. ??? ?̸? ???Ͽ? 2021?? 5?????? 6?????? ?????? ?????, ??ġ???? ?ٹ??ϴ? ?????Ʊ??? 500???? ??????? ???????縦 ?ǽ??Ͽ???. ?????? ?ڷ?? ?????????? ?ŷڵ??? ?????ϱ? ???Ͽ? Cronbach??s ?? ????? ?????Ͽ???, ?ǻ???? ??ֿ??ο? ???? ?ν?, ???? ???? ???? ?νİ? ?????? ???̸? ?˾ƺ??? ???? ?Ͽ??????м??? ????ǥ?? t?????? ?ǽ??Ͽ? ?м??Ͽ???. ??? ù°, ??????? ????μ??? ?ǻ?????? ???? ???ذ? ?и??ϰ?, ?????????? ???ؼ??? ?и??? ?ν??ϰ? ?־???. ??°, ?????Ʊ????? ???????? ???? ?ǻ???? ?νİ? ?????? ??? ?? ?˾ƺ? ???, ????μ? ??õ?ؾ? ?ϴ? ?⺻???? ?????? ?־ ?νİ? ????????? ???? ?????? ??Ÿ?????? ?̿??? ?????? ?־?? ?ǻ???? ?????? ???Ͽ? ?ټ? ?߿䵵?? ???? ?ν? ?? ?????ϰ? ?ִ? ?????? ??Ÿ????. ??°, ?????Ʊ????? ???????? ???? ?ǻ?????? ???? ?νİ? ??? ???̰? ?ִ??? ?˾ƺ? ??? ???????? ?νļ????? ??????ؿ? ???? ???? ?????? ??Ÿ????. ??? ?????Ʊ?????? ?ǻ???? ?????? ???? ?ν? ?? ??ֿ???, ?????????? ???? ?νİ? ??? ???Ͽ? ???캸?Ҵٴ? ?????? ???ǰ? ?????? ????? ???? ???忡?? ?????? ?ǻ???? ?????? ???? ȯ???????? ??????ȿ? ???? ?û????? ?????Ͽ???.
- 15 May 2022
- Published by Korean Association For Learner-Centered Curriculum And Instruction in Korean Association For Learner-Centered Curriculum And Instruction
- Vol. 22 (9) , 59-78
The Perception and Practice of Early Childhood Teacher’s Decision-Making Involvement
???? ?? ?????? ?????Ʊ?????? ?ǻ???? ?????? ???? ?νİ? ?????? ????? ?˾ƺ??? ?? ?????? ?ξ???. ??? ?̸? ???Ͽ? 2021?? 5?????? 6?????? ?????? ?????, ??ġ???? ?ٹ??ϴ? ?????Ʊ??? 500???? ??????? ???????縦 ?ǽ??Ͽ???. ?????? ?ڷ?? ?????????? ?ŷڵ??? ?????ϱ? ???Ͽ? Cronbach??s ?? ????? ?????Ͽ???, ?ǻ???? ??ֿ??ο? ???? ?ν?, ???? ???? ???? ?νİ? ?????? ???̸? ?˾ƺ??? ???? ?Ͽ??????м??? ????ǥ?? t?????? ?ǽ??Ͽ? ?м??Ͽ???. ??? ù°, ??????? ????μ??? ?ǻ?????? ???? ???ذ? ?и??ϰ?, ?????????? ???ؼ??? ?и??? ?ν??ϰ? ?־???. ??°, ?????Ʊ????? ???????? ???? ?ǻ???? ?νİ? ?????? ??? ?? ?˾ƺ? ???, ????μ? ??õ?ؾ? ?ϴ? ?⺻???? ?????? ?־ ?νİ? ????????? ???? ?????? ??Ÿ?????? ?̿??? ?????? ?־?? ?ǻ???? ?????? ???Ͽ? ?ټ? ?߿䵵?? ???? ?ν? ?? ?????ϰ? ?ִ? ?????? ??Ÿ????. ??°, ?????Ʊ????? ???????? ???? ?ǻ?????? ???? ?νİ? ??? ???̰? ?ִ??? ?˾ƺ? ??? ???????? ?νļ????? ??????ؿ? ???? ???? ?????? ??Ÿ????. ??? ?????Ʊ?????? ?ǻ???? ?????? ???? ?ν? ?? ??ֿ???, ?????????? ???? ?νİ? ??? ???Ͽ? ???캸?Ҵٴ? ?????? ???ǰ? ?????? ????? ???? ???忡?? ?????? ?ǻ???? ?????? ???? ȯ???????? ??????ȿ? ???? ?û????? ?????Ͽ???.
- Open Access
- 6 May 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-10
Dietary antigens suppress the proliferation of type 2 innate lymphoid cells by restraining homeostatic IL-25 production
Dietary antigens affect the adaptive immunity of the host by inducing regulatory T cells and IgE-producing B cells. However, their roles in innate immune compartments such as innate lymphoid cells (ILCs) and intestinal epithelial cells (IECs) are unclear. Here, using antigen-free (AF) mice, which are germ-free (GF) mice fed with amino-acid-based diet, we found dietary proteins suppress the development of GATA-3-expressing ILC2s independent of the adaptive immune cells. These cells produce more type 2 cytokines and upregulated proliferation and activation markers such as Ki-67, CD69, and CD25. With this, AF mice had increased expressions of tuft cell-specific transcripts such as Il25, Il33, Dclk1, Trpm5, and Pou2f3 in IECs. Accordingly, expanded ILC2s upregulated IL-17RB, a receptor of IL-25, and their proliferation was blocked by IL-25 neutralizing or IL-17RB blocking antibodies. These results suggest a new dialogue between dietary antigens, IECs, and ILCs in which dietary antigens suppress ILC2 activation and proliferation by restraining homeostatic IL-25 production, potentially limiting type 2 immunity by food antigens.
- 6 May 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-10
Open AccessDietary antigens suppress the proliferation of type 2 innate lymphoid cells by restraining homeostatic IL-25 production
Dietary antigens affect the adaptive immunity of the host by inducing regulatory T cells and IgE-producing B cells. However, their roles in innate immune compartments such as innate lymphoid cells (ILCs) and intestinal epithelial cells (IECs) are unclear. Here, using antigen-free (AF) mice, which are germ-free (GF) mice fed with amino-acid-based diet, we found dietary proteins suppress the development of GATA-3-expressing ILC2s independent of the adaptive immune cells. These cells produce more type 2 cytokines and upregulated proliferation and activation markers such as Ki-67, CD69, and CD25. With this, AF mice had increased expressions of tuft cell-specific transcripts such as Il25, Il33, Dclk1, Trpm5, and Pou2f3 in IECs. Accordingly, expanded ILC2s upregulated IL-17RB, a receptor of IL-25, and their proliferation was blocked by IL-25 neutralizing or IL-17RB blocking antibodies. These results suggest a new dialogue between dietary antigens, IECs, and ILCs in which dietary antigens suppress ILC2 activation and proliferation by restraining homeostatic IL-25 production, potentially limiting type 2 immunity by food antigens.
- 27 September 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 5173-5180
Real-Time Physically-Accurate Simulation of Robotic Snap Connection Process
We propose a novel real-time physically-accurate simulation framework for the snap connection process. For this, we first notice the peculiarities of the process, namely, small/smooth deformation, stiff connector and segmented contact. We then design our simulation to fully exploit these peculiarities by adopting the following strategies: 1) the technique of passive midpoint integration (PMI [1]), which allows for stable simulation of arbitrarily light/stiff system by enforcing discrete-time passivity; 2) linear finite element method (FEM [2]) modeling, which is adequate to deal with the small snap connector deformation while providing much faster speed as compared to nonlinear FEM; 3) segmentation of the snap connector FEM model and solving of each segment individually with their coupling analytically eliminated, thereby, further speeding up the simulation; 4) balanced model reduction (BMR [3]) to further reduce the dimension of each segment purely analytically without any prior experiment or simulation; and 5) parallelized data-driven collision detection, which turns out to further significantly speed up our simulation. Experimentally-verified simulations are also performed to show the efficacy of our proposed simulation framework.
- 27 September 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 5173-5180
Real-Time Physically-Accurate Simulation of Robotic Snap Connection Process
We propose a novel real-time physically-accurate simulation framework for the snap connection process. For this, we first notice the peculiarities of the process, namely, small/smooth deformation, stiff connector and segmented contact. We then design our simulation to fully exploit these peculiarities by adopting the following strategies: 1) the technique of passive midpoint integration (PMI [1]), which allows for stable simulation of arbitrarily light/stiff system by enforcing discrete-time passivity; 2) linear finite element method (FEM [2]) modeling, which is adequate to deal with the small snap connector deformation while providing much faster speed as compared to nonlinear FEM; 3) segmentation of the snap connector FEM model and solving of each segment individually with their coupling analytically eliminated, thereby, further speeding up the simulation; 4) balanced model reduction (BMR [3]) to further reduce the dimension of each segment purely analytically without any prior experiment or simulation; and 5) parallelized data-driven collision detection, which turns out to further significantly speed up our simulation. Experimentally-verified simulations are also performed to show the efficacy of our proposed simulation framework.
- Open Access
- 3 May 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (5) , eaaw1507
Food antigens drive spontaneous IgE elevation in the absence of commensal microbiota
Immunoglobulin E (IgE), a key mediator in allergic diseases, is spontaneously elevated in mice with disrupted commensal microbiota such as germ-free (GF) and antibiotics-treated mice. However, the underlying mechanisms for aberrant IgE elevation are still unclear. Here, we demonstrate that food antigens drive spontaneous IgE elevation in GF and antibiotics-treated mice by generating T helper 2 (TH2)–skewed T follicular helper (TFH) cells in gut-associated lymphoid tissues (GALTs). In these mice, depriving contact with food antigens results in defective IgE elevation as well as impaired generation of TFH cells and IgE-producing cells in GALT. Food antigen–driven TFH cells in GF mice are mostly generated in early life, especially during the weaning period. We also reveal that food antigen–driven TFH cells in GF mice are actively depleted by colonization with commensal microbiota. Thus, our findings provide a possible explanation for why the perturbation of commensal microbiota in early life increases the occurrence of allergic diseases.
- 3 May 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (5) , eaaw1507
Open AccessFood antigens drive spontaneous IgE elevation in the absence of commensal microbiota
Immunoglobulin E (IgE), a key mediator in allergic diseases, is spontaneously elevated in mice with disrupted commensal microbiota such as germ-free (GF) and antibiotics-treated mice. However, the underlying mechanisms for aberrant IgE elevation are still unclear. Here, we demonstrate that food antigens drive spontaneous IgE elevation in GF and antibiotics-treated mice by generating T helper 2 (TH2)–skewed T follicular helper (TFH) cells in gut-associated lymphoid tissues (GALTs). In these mice, depriving contact with food antigens results in defective IgE elevation as well as impaired generation of TFH cells and IgE-producing cells in GALT. Food antigen–driven TFH cells in GF mice are mostly generated in early life, especially during the weaning period. We also reveal that food antigen–driven TFH cells in GF mice are actively depleted by colonization with commensal microbiota. Thus, our findings provide a possible explanation for why the perturbation of commensal microbiota in early life increases the occurrence of allergic diseases.
- Open Access
- 1 July 2018
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 11 (7) , dmm033241
HIF-1α activation in myeloid cells accelerates dextran sodium sulfate-induced colitis progression in mice
Inflammatory bowel disease (IBD) is a chronic inflammatory disease, in which the intestinal epithelium loses its barrier function. Given the existence of the oxygen gradient in the intestinal epithelium and that inflammation further contributes to the tissue hypoxia, we investigated the role of hypoxia-inducible factor (HIF), a transcription factor activated under hypoxic conditions in myeloid cells, in the progression of IBD. To do this, we utilized myeloid-specific knockout (KO) mice targeting HIF pathways, created by a Cre-loxP system with human MRP8 (hMRP8), an intracellular calcium-binding protein, as the myeloid promoter. By feeding 5% dextran sodium sulfate (DSS) to hMRP8 von Hippel Lindau (Vhl) KO mice, in which HIF-1α and HIF-2α are constitutively activated in myeloid cells, we found that these mice were highly susceptible to DSS-induced colitis, demonstrating greater body weight loss, increased mortality, faster onset of rectal bleeding, shortened colon length, and increased CD11b- or Gr-1-positive myeloid cells in the colon compared with wild-type (WT) mice. These parameters were restored to, if not better than, the WT levels when we examined hMRP8 Hif-1a KO mice upon 5% DSS feeding. hMRP8 Hif-2a KO mice, on the other hand, exhibited a similar degree of DSS-induced colitis to that of WT mice. Lastly, when DSS was given together with azoxymethane to induce tumorigenesis in the colon, we found that hMRP8 Hif-1a KO mice exhibited comparable levels of colorectal tumors to those of WT mice, indicating that HIF-1α in myeloid cells is dispensable for tumorigenesis. Collectively, our results suggest that HIF-1α activation in myeloid cells critically regulates IBD progression.
- 1 July 2018
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 11 (7) , dmm033241
Open AccessHIF-1α activation in myeloid cells accelerates dextran sodium sulfate-induced colitis progression in mice
Inflammatory bowel disease (IBD) is a chronic inflammatory disease, in which the intestinal epithelium loses its barrier function. Given the existence of the oxygen gradient in the intestinal epithelium and that inflammation further contributes to the tissue hypoxia, we investigated the role of hypoxia-inducible factor (HIF), a transcription factor activated under hypoxic conditions in myeloid cells, in the progression of IBD. To do this, we utilized myeloid-specific knockout (KO) mice targeting HIF pathways, created by a Cre-loxP system with human MRP8 (hMRP8), an intracellular calcium-binding protein, as the myeloid promoter. By feeding 5% dextran sodium sulfate (DSS) to hMRP8 von Hippel Lindau (Vhl) KO mice, in which HIF-1α and HIF-2α are constitutively activated in myeloid cells, we found that these mice were highly susceptible to DSS-induced colitis, demonstrating greater body weight loss, increased mortality, faster onset of rectal bleeding, shortened colon length, and increased CD11b- or Gr-1-positive myeloid cells in the colon compared with wild-type (WT) mice. These parameters were restored to, if not better than, the WT levels when we examined hMRP8 Hif-1a KO mice upon 5% DSS feeding. hMRP8 Hif-2a KO mice, on the other hand, exhibited a similar degree of DSS-induced colitis to that of WT mice. Lastly, when DSS was given together with azoxymethane to induce tumorigenesis in the colon, we found that hMRP8 Hif-1a KO mice exhibited comparable levels of colorectal tumors to those of WT mice, indicating that HIF-1α in myeloid cells is dispensable for tumorigenesis. Collectively, our results suggest that HIF-1α activation in myeloid cells critically regulates IBD progression.